Oral Solubilization Technology: New Pfizer Licensing Initiative
THE TECHNOLOGY TO ADVANCE. THE OPPORTUNITY TO SUCCEED.
 Announcing
a new licensing opportunity for low-solubility compounds using a novel
technology to improve oral bioavailability. This technology, which is based on
spray-dried dispersions (SDDs), has been successfully used to improve the oral
bioavailability of hundreds of low-solubility compounds, including more than 20
in clinical trials.
Through this initiative, companies interested can evaluate the effectiveness
of the SDD technology for delivery of their compounds. For more information,
please see the
printable PDF brochure describing this opportunity.
|
